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Abstract
Carnosinase 1 (CN1) has been postulated to be a susceptibility factor for developing diabetic nephropathy (DN). Although its 
major substrate, carnosine, is beneficial in rodent models of DN, translation of these findings to humans has been hampered 
by high CN1 activity in human serum resulting in rapid degradation of carnosine. To overcome this hurdle, we screened a 
protease-directed small-molecule library for inhibitors of human recombinant CN1. We identified SAN9812 as a potent and 
highly selective inhibitor of CN1 activity with a Ki of 11 nM. It also inhibited CN1 activity in human serum and serum of 
transgenic mice-overexpressing human CN1. Subcutaneous administration of 30 mg/kg SAN9812 led to a sustained reduction 
in circulating CN1 activity in human CN1 transgenic (TG) mice. Simultaneous administration of carnosine and SAN9812 
increased carnosine levels in plasma and kidney by up to 100-fold compared to treatment-naïve CN1-overexpressing mice. 
To our knowledge, this is the first study reporting on a potent and selective CN1 inhibitor with in vivo activity. SAN9812, 
also called carnostatine, may be used to increase renal carnosine concentration as a potential therapeutic modality for renal 
diseases linked to glycoxidative conditions.
Keywords Diabetic nephropathies · Carnosine · Aminoacyl-histidine dipeptidase · Drug discovery
Introduction
The rising global prevalence of type 2 diabetes (T2D) is 
accompanied by an increase in diabetic complications, 
such as diabetic nephropathy (DN), the single most com-
mon cause of end-stage renal disease (ESRD). Despite our 
continuously evolving understanding of the pathogenesis of 
DN and potential interventions, the current standard of care 
has largely failed to achieve stable long-term results, and a 
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strong unmet need for novel and more efficacious therapies 
remains (de Zeeuw and Heerspink 2016).
Carnosine (β-alanyl-l-histidine) is a physiological dipep-
tide first discovered in meat extract more than 100 years ago 
(Gulewitsch and Amiradžibi 1900). It is primarily found in 
skeletal muscle where its content can be as high as 2 g/kg 
wet tissue or 0.2% of overall skeletal muscle mass (Boldyrev 
et al. 2013). It is also present in other tissues such as brain, 
kidney or spleen albeit at 10- to 100-fold lower concen-
trations (Kamal et al. 2009). Properties pertaining to the 
physiological roles of carnosine include its pH-buffering 
capacity, scavenging of reactive oxygen species (ROS) and 
peroxyl radicals, metal-ion chelation and protection against 
advanced glycation and lipoxidation end products (AGE 
and ALE, Boldyrev et al. 2013). Notably, carnosine has also 
been demonstrated to reverse pre-formed glycated proteins 
(Seidler et al. 2004). In line with its role in muscle physiol-
ogy, food supplements containing carnosine or its precur-
sor beta-alanine improve exercise performance in untrained 
individuals (Hill et al. 2007) as well as in elite athletes (Van 
Thienen et al. 2009; Baguet et al. 2010). Due to its metal-
ion chelating and anti-oxidative properties, carnosine can 
ameliorate transition metal-catalysed- or hyperglycaemia-
mediated oxidative stress which may occur in several (path-
ologic) conditions such as diabetes and its complications 
(Zhang et al. 2016). Apart from the nutritional intake, tissue 
carnosine concentration also depends on the activity of local 
carnosine synthase, an ATP-dependent enzyme, as shown 
for a variety of tissues, e.g., skeletal muscle, brain or kidney 
(Drozak et al. 2010; Peters et al. 2015).
Carnosinase (CN1, EC 3.4.13.20) is the major carnosine-
degrading enzyme. The human gene was cloned in 2003 and 
identified as the gene encoding the secreted form of carnosi-
nase (Teufel et al. 2003). By positional cloning in a large 
Turkish family affected by DN, the carnosine dipeptidase 
1 gene (CNDP1) was identified as a susceptibility gene for 
developing DN (Vardarli et al. 2002; Janssen et al. 2005). 
The leucine repeat in the signal sequence of CNDP1 gene 
is essential for CN1 secretion with the short allelic vari-
ant (CTG)5 associated with low-serum CN1 concentrations. 
Importantly, patients with T2D without DN are significantly 
more frequently homozygous for the (CTG)5 allele (Freed-
man et al. 2007; Riedl et al. 2007; Alkhalaf et al. 2010; 
Peters et al. 2016). It was postulated that low CN1 activity 
might favour high circulating carnosine concentrations. Of 
note, in a carnosine or beta-alanine supplementation study in 
rats with diet-induced obesity, it was recently demonstrated 
that plasma rather than muscle carnosine is involved in ame-
liorating high-fat diet-induced lipoxidative and inflammatory 
stress (Stegen et al. 2015). Carnosine supplementation stud-
ies in murine models demonstrated therapeutic efficacy of 
carnosine to ameliorate diabetes and DN, as albuminuria and 
histological lesions were reduced after supplementation (Lee 
et al. 2005; Alhamdani et al. 2007; Sauerhöfer et al. 2007; 
Riedl et al. 2011; Aldini et al. 2011; Nagai et al. 2012; Peters 
et al. 2012; Albrecht et al. 2017).
However, rodents—with the exception of Syrian ham-
ster—lack the signal peptide in the CN1 gene and conse-
quently do not have CN1 in the circulation (Boldyrev et al. 
2013). This results in increased carnosine levels after oral 
carnosine supplementation (Albrecht et al. 2017). In con-
trast, carnosine supplementation in humans leads only to 
a small increase in circulating carnosine because of its fast 
degradation by serum CN1 (Everaert et al. 2011). Because of 
this difference, extrapolation of rodent findings to humans is 
difficult. As T2D patients have even higher serum CN1 activ-
ity levels compared to healthy controls (Riedl et al. 2010), 
CN1 inhibition could be a potential strategy to increase the 
serum concentration of carnosine, especially in combination 
with carnosine supplementation. So far, this possibility has 
not been explored due to the lack of a specific CN1 inhibitor. 
Here, we describe the identification and characterisation of 
a potent and selective CN1 inhibitor, carnostatine, and its 
effect on serum CN1 activity and carnosine levels in serum 
and renal tissue after co-administration with carnosine.
Results
We screened a protease-directed small-molecule library con-
taining 6080 compounds for inhibitors of human recombi-
nant CN1 using a screening assay based on the detection 
of histidine generated by proteolytic cleavage of carnosine 
(supplementary methods). The human recombinant CNDP1 
showed a Km value of 190 μM (supplementary figure 1), 
similar to the previously reported value of 175 µM (Peters 
et al. 2010). The average Z′ value (± SD) of all 38 test plates 
was 0.85 ± 0.06 (supplementary figure 2), indicating that 
the assay was of excellent robustness (Zhang et al. 1999). 
Results are summarised in Fig. 1. In total, we identified 133 
compounds with > 50% inhibition. These compounds were 
re-tested in duplicates (supplementary figure 3).
One of the most potent compounds identified was 
SAN9812 (Fig. 2), with an  IC50 value of 18 nM on human 
recombinant CN1 at a carnosine concentration of 200 µM, 
i.e., close to the Km of 190 µM. SAN9812 was found to be a 
competitive inhibitor, showing a right-shift in its  IC50 value 
with increasing carnosine concentration (Fig. 3a). The Ki 
value of SAN9812 was determined as 11 nM (Fig. 3b). The 
synthesis of SAN9812 is described in supplementary fig-
ure 4 and supplementary methods. 
The inhibitory activity of SAN9812 on human CN1 
was confirmed in serum from TG mice-expressing human 
CN1 and serum from healthy human volunteers (Fig. 3c, 
d).  IC50 values were determined as 650 and 340  nM, 
respectively, at a carnosine concentration of 0.2 mg/ml or 
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880 µM. The average baseline hCN1 activities in transgenic 
mice and healthy human volunteers were 137 ± 25 and 
1.1 ± 0.25 µmol/ml/h, respectively.
Of note, SAN9812 was found to be inactive on a standard 
panel of 33 different receptors, channels, transporters and 
enzymes (supplementary Table 1) when tested at a concen-
tration of 10 µM, reflecting overall selectivity of SAN9812 
and ruling out that it is a modulator of a broad spectrum of 
biological activities. The ADME/PK (absorption, distribu-
tion, metabolism, excretion and pharmacokinetics) profile 
of SAN9812 is summarised in Table 1. The compound is 
very stable in human, rat and mouse liver microsomes and 
shows moderate clearance in primary human hepatocytes. 
Permeability in the CaCo-2 assay as a measurement of intes-
tinal permeability was determined as 17.9 nm/s, indicating 
moderate oral absorption potential.
Plasma levels of SAN9812 after single bolus adminis-
tration of either 3 mg/kg i.v. or 30 mg/kg s.c. are shown 
in Fig. 4a. Clearance, volume of distribution and subcu-
taneous bioavailability are summarised in Table 1. After 
subcutaneous injection, maximal plasma concentrations 
were achieved already at the first sampling time point 
after administration (15 min). The maximal compound 
concentration after s.c. administration was 80  μg/ml, 
corresponding to approximately 300  μM. Plasma lev-
els quickly decrease to 30 μg/ml (120 μM) after 30 min, 
5.7 μg/ml (22 μM) after 1 h, and 350 ng/ml (1.4 μM) after 
2 h. The lower level of quantification for the detection 
method was 10 ng/ml (40 nM). After intravenous injection, 
maximal plasma concentration was also observed at the 
first sampling time point, but there was a fast decrease in 
plasma SAN9812 concentrations reflecting rapid clearance 
of the compound from the circulation. Further experiments 
were performed using subcutaneous injection due to the 
longer availability of the compound in the blood.
In a subsequent pharmacodynamics study, CN1 activity 
was measured after a single subcutaneous bolus of 30 mg/
kg SAN9812, at the same time points as previously in the 
PK experiment. Results are shown in Fig. 4b, c. Animals 
were stratified according to their baseline serum carnosi-
nase activity into a high-activity- (> 250 µmol/ml/h) and a 
low-activity (< 45 µmol/ml/h) group. Mean baseline activ-
ities in the two groups were 259 ± 13 and 7.4 ± 4.9 µmol/
ml/h, respectively. Administration of SAN9812 led to a 
rapid reduction in serum carnosinase activity by more than 
90% in both groups which was sustained for > 8 h. At the 
last sampling time point 16 h after compound administra-
tion, serum carnosinase activity was still reduced by 40% 
in the low-activity group and by 75% in the high-activity 
group.
SAN9812 was then subcutaneously administered over 
7 days once daily at a dose of 30 mg/kg. Blood samples were 
taken on days 1, 4 and 7 before, 6 and 12 h after the injection 
to measure CN1 activity. The results are depicted in Fig. 5. 
Again, CN1 activity was strongly and rapidly reduced after 
the first SAN9812 injection on day 1 and remained low over 
a period of > 12 h. Importantly, baseline CN1 activities on 
days 4 and 7, measured 24 h after the previous SAN9812 
administration on days 3 and 6, respectively, were consider-
ably lower compared to CN1 activity on day 1 before the 
Fig. 1  a Distribution of mean percent-inhibition values in the screen of 6080 compounds for inhibitors of human recombinant CN1. b Compari-
son of percent-inhibition values obtained in duplicate experiments
Fig. 2  Structure of SAN9812
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first injection, indicating sustained carnosinase inhibition 
over 24 h in both the low-activity and high-activity groups.
The same average inhibition in percent was achieved 
in the group with low-baseline activity as in the group 
with high-baseline activity. In mice with low-baseline 
activity, CN1 activity was efficaciously inhibited over 
the whole observation period with an activity level kept 
below 10 µmol/ml/h. In the group with high-baseline activ-
ity levels, absolute CN1 activity could sometimes exceed 
100 µmol/ml/h between injections, although percent-inhibi-
tion values were comparable in all animals (Fig. 5).
We did not note any obvious adverse effects of treatment 
with SAN9812 over 7 days, body weight and blood glucose 
were not different between treated and untreated animals.
To determine whether serum CN1 inhibition by SAN9812 
can increase carnosine concentration in vivo in hCN1 over-
expressing mice, animals were given a single bolus of 
200 mg carnosine alone or in combination with 30 mg/kg 
SAN9812 per s.c. injection. Plasma samples were taken 4 
and 8 h after injection. Kidneys were harvested 8 h after 
injection. CN1-negative wild type mice and hCN1 mice 
without treatment served as controls.
Compared to wild type animals, hCN1 TG mice had sig-
nificantly lower plasma carnosine levels (Fig. 6a, b). A simi-
lar, but non-significant trend was also seen for the kidney 
(Fig. 6c). As shown in Fig. 6a, in hCN1 mice after a single 
Fig. 3  a Concentration–response curves for SAN9812 determined at 
100 µM (open triangles) and 1000 µM (filled squares) carnosine with 
human recombinant CN1 in PBS (n = 6 each), corresponding  IC50 
values were determined as 10 and 54 nM, respectively. b Dependence 
of SAN9812  IC50 values on carnosine concentration (n = 6 each). 
The Ki values defined as the intersection of the linear regression line 
(R2 = 0.91) with the y-axis was determined as 11  nM. c Concentra-
tion–response curve of SAN9812 in serum from transgenic mice-
expressing human CN1 (three replicates from three mice), and d 
in human serum (three replicates from two subjects) at a carnosine 
concentration of 880  µM (0.2  mg/ml).  IC50 values were determined 
as 650 and 340 nM, respectively. Data are presented as mean ± SEM
Table 1  ADME and PK profile of SAN9812
a At a concentration of 10 µM vs a panel of 33 diverse receptors, ion 
channels, transporters and enzymes
Metabolic stability h/r/m microsomes (% remaining) 100/94/99
Human hepatocyte clearance (ml/h/106 cells) 0.032
Caco-2 permeability (nm/s) 17.9
Clearance (mL/min/kg) 0.344
Volume of distribution (L/kg) 0.122
Subcutaneous bioavailability (%) 42.5
Selectivity panel Inactivea
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subcutaneous bolus of carnosine, the plasma carnosine 
concentration increased compared to hCN1-overexpressing 
controls without carnosine administration (p = 0.049) 4 h 
after injection but was still lower compared to wild type 
mice without injection (p = 0.058). In contrast, a concurrent 
administration of carnosine and SAN9812 led to a further 
increase in carnosine plasma concentration, up to the levels 
of hCN1-negative controls without injection 4 h after admin-
istration. 8 h after concurrent administration of carnosine 
and SAN9812, plasma carnosine levels had returned to lev-
els of hCN1 controls probably due to residual CN1 activity 
(mean ± SD 14.4 ± 15.7 µmol/ml/h). Mean CN1 activity in 
hCN1 mice was 55.3 ± 30.6 µmol/ml/h.
As shown in Fig. 6c, in the kidney concurrent adminis-
tration of carnosine and SAN9812 significantly increased 
carnosine concentration (mean ± SD 3.5 ± 2.3  nmol/
mg) compared to wild type controls without any treat-
ment (0.32 ± 0.46 nmol/mg), hCN1-overexpressing mice 
(0.034 ± 0.028 nmol/mg) and also hCN1-overexpressing 
mice supplemented with carnosine (0.52 ± 1.2) (p < 0.005). 
Of note, kidneys were removed 8 h after injection when 
plasma carnosine levels had already returned to normal.
Discussion
In this work, we discovered carnostatine (SAN9812) as 
a potent and selective CN1 inhibitor with a Ki of 11 nM 
for human recombinant CN1. Subcutaneous injection of 
SAN9812 led to a sustained reduction in serum carnosinase 
activity in transgenic mice overexpressing human CN1, both 
acutely as well as upon subchronic treatment. Additionally, a 
combination of carnosine and carnostatine caused a further 
increase in serum carnosine concentration and, for a disease 
such as DN most importantly, an increase of carnosine levels 
in renal tissue.
Carnosinase 1 has attracted considerable interest through 
the discovery in humans that a polymorphism of CN1 asso-
ciated with lower serum CN1 concentrations protects against 
DN. In keeping with the hypothesis that low serum CN1 
concentration may protect patients with type 2 diabetes from 
developing DN, the rationale of the current study was to gen-
erate a potent CN1 inhibitor as a potential drug candidate for 
preventing or slowing down the progression of DN.
The protective effect of a genotype with lower CN1 
activity, as shown in large cross-sectional studies, is likely 
Fig. 4  a Plasma levels of SAN9812 after single bolus administration 
of either 3 mg/kg i.v. or 30 mg/kg s.c. (n = 3 each). The lower level 
of quantification for the detection method was 10  ng/ml (40  nM). 
Data are shown as mean ± standard deviation. b, c Serum carnosi-
nase activity before and after a single s.c. bolus injection of 30 mg/
kg SAN9812. Absolute activities are shown in b for mice with low-
serum carnosinase activity (< 45 µmol/ml/min, n = 3) or high-serum 
carnosinase activity (> 250  µmol/ml/min, n = 3). Percent-activity 
values from the same set of experiments are shown in (c). Data are 
depicted as mean ± SEM
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Fig. 5  Subchronic (7  days) administration of SAN9812 (30  mg/
kg  s.c. q.d.) inhibits serum CN1 activity. a Serum CN1 activ-
ity (relative to day 1 baseline) prior to, 6 and 12 h after compound 
administration on days 1, 4 or 7 for all mice investigated (n = 10, 
mean ± SEM). b, c Individual absolute CN1 activities for the high-
activity (b, n = 5) and the low-activity (c, n = 5) group of hCN1-
expressing transgenic mice
Fig. 6  Plasma and renal tissue carnosine concentration upon sub-
cutaneous carnosine supplementation (CAR) with and without 
SAN9812 administration in hCN1 overexpressing (CN1+) mice 
(n = 5–8 per group). hCN1-negative wild type mice (CN1−) served 
as controls. The lower level of quantification for the detection method 
was 0.0001  nmol/mg. Data are shown as mean ± SD. a Plasma car-
nosine concentration 4  h and b 8  h after administration of carnos-
ine ± SAN9812. c Carnosine concentration in the kidney harvested 
8 h after injection. One-way ANOVA followed by Dunnett’s multiple 
comparisons test was performed using GraphPad Prism (*p < 0.05, ** 
for p < 0.01)
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mediated by an increase in serum carnosine concentration. 
To increase serum carnosine, many carnosine supplementa-
tion studies have been conducted in rodent models. However, 
as rodents lack the signal peptide in the CN1 gene and con-
sequently do not have CN1 in the circulation (Boldyrev et al. 
2013), the translation of these findings to humans is difficult. 
Unlike rodents, humans have considerable serum CN1 activ-
ity which may even be higher in particular disease states, 
e.g., in diabetic individuals compared to healthy controls 
(Riedl et al. 2010). Thus, as observed in healthy volunteers, 
carnosine supplementation only leads to a moderate increase 
in plasma carnosine for a limited period of time between 1 
and 2 h because of its rapid degradation by CN1 (Everaert 
et al. 2012) that may markedly limit carnosine’s beneficial 
effects in humans.
Several human trials in the field of sports medicine have 
been conducted, either with carnosine or beta-alanine, the 
rate-limiting precursor for endogenous carnosine synthesis, 
and showed beneficial effects on exercise performance (Hill 
et al. 2007; Van Thienen et al. 2009; Baguet et al. 2010). 
Although muscle carnosine was not measured in our study, 
the marked increase by 100-fold in renal tissue concentration 
of carnosine by simultaneous administration of carnosine 
and a CN1-specific inhibitor, although in an artificial set-
ting, was promising and suggests that our approach may also 
enhance the beneficial effects of carnosine in other tissues.
Other human trials have shown a positive effect of carno-
sine supplementation on insulin sensitivity in obese human 
individuals (De Courten et al. 2016; Regazzoni et al. 2016). 
Because of the reasons given above, an additional CN1 inhi-
bition may further increase these beneficial effects. So far, 
this has not been studied because of the lack of a specific 
CN1 inhibitor. Here, we describe SAN9812, a specific CN1 
inhibitor as a new tool for such studies. As SAN9812 can 
stabilise carnosine levels both in plasma and kidney tissue 
after co-administration with carnosine, we propose to use 
the name carnostatine for SAN9812.
In the current work, carnostatine and carnosine were sub-
cutaneously injected. The oral availability of carnostatine 
has so far not been investigated. Oral absorption potential of 
carnostatine, based on Caco-2 permeability, was found to be 
moderate but high enough to merit additional studies where 
the compound could be given via oral gavage or drinking 
water. Especially the latter option would make it feasible to 
perform chronic treatment studies with minimal compound 
application stress for the study animals.
Possible side effects of carnostatine could be similar to 
carnosinemia, where a lack of carnosinase is associated 
with several neurological symptoms. Although we could 
not detect any major side effects after 7 days of carnos-
tatine treatment in mice, we could not exclude any neuro-
logical symptoms since no behaviour test was performed. 
Moreover, CN1 is postulated to play a major role in brain 
gamma-aminobutyric acid (GABA)-ergic system as it can 
release GABA by degrading homocarnosine. If carnos-
tatine can bypass the blood–brain-barrier, it could interfere 
with this system and cause GABA-deficiency symptoms 
such as depression, anxiety or panic. In addition, pathways 
involving other degradation products of CN1, e.g., histi-
dine or beta-alanine could be influenced.
The model system used in our study—mice-overex-
pressing human CN1—is reflecting the situation in humans 
where plasma carnosinase activity can be detected. How-
ever, the model also has certain limitations, such as the 
high variability of CN1 activity and a high absolute plasma 
CN1 activity compared to lean human volunteers. Thus, 
care should be taken to stratify animal according to CN1 
activity and to select animals with moderately increased 
CN1 activity for further chronic studies.
To our knowledge, this is the first in vivo active car-
nosinase inhibitor described. This CN1 inhibitor is potent 
with a Ki of 11 nm and specific with no reactivity vs. a 
panel of 33 different receptors, channel transporters and 
enzymes. So far, our studies were limited to healthy ani-
mals and short treatment periods. It will be interesting to 
see whether chronic carnosinase inhibition, especially if 
carnostatine is orally administered in combination with 
carnosine, can protect from diabetic nephropathy as seen 
in carnosine supplementation studies in mice devoid of 




Human CNDP1 transgenic mice on a BTBR wt/ob back-
ground (Jackson Laboratory Stock number: 004824) were 
used for the experiments. These mice express human CN1 
in brain and liver from where it is secreted into the blood. 
The generation and characterisation of these hCN1 over-
expressing mice will be described in a separate paper. The 
animals were housed in a 12-h light/dark cycle at 22 °C 
and sacrificed under isoflurane anaesthesia by neck dis-
location. Animals between 8 and 10 weeks of age with 
a body weight of 25–35 g were used. For the experiment 
with carnosine ± carnostatine injection age- and sex-
matched animals were used. Body weight and blood glu-
cose were measured between the injections to detect major 
abnormalities of animal well-being. No difference between 
two groups was detected.
14 J. Qiu et al.
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Human
Serum samples were taken from two healthy donors 
(one male, one female) that were 25 and 26 years of age, 
respectively.
High‑throughput screening and compound 
characterisation
We screened a protease-directed small compound library 
using human recombinant carnosinase 1 based on an assay 
described by Teufel 2002. Details are described in sup-
plementary methods.  IC50 and Ki values and the mode of 
inhibition by SAN9812 were determined as described in 
supplementary methods. Activity of SAN9812 on a stand-
ard panel of 33 different receptors, channels, transporters 
and enzymes was measured at Eurofins Pharma Discovery 
Services. Detailed descriptions of individual assays can 
be found at https ://www.eurofi nsdi scove ryser vices .com.
Activity of SAN9812 in human and mouse serum
To determine the concentration–response curve of 
SAN9812, serum from two healthy donors and three CN1-
transgenic mice were used. SAN9812 was diluted with 
PBS and added to the serum directly (2–3 s) before meas-
uring the CN1 activity.
ADME profile of SAN9812
A detailed description of the methods used to investigate 
the ADME profile can be found in the supplementary 
methods.
Pharmacokinetics
Pharmacokinetic parameters were determined in female 
C57BL/6 mice (Harlan, Germany). After a single admin-
istration of either 3 mg/kg i.v. or 30 mg/kg  s.c. of test 
compound dissolved in phosphate-buffered saline, pH 7.4, 
plasma samples were taken at eight time points over 24 h. 
Three animals per time point were used. Concentrations of 
the test compound were determined with an exploratory 
LC–MS/MS method using an internal standard. Clearance 
and volume of distribution were determined based on the i.v. 
pharmacokinetics, subcutaneous bioavailability by compar-
ing the area under the curve after subcutaneous vs. intra-
venous administration. Pharmacokinetic parameters were 
calculated using the program WinNonlin 6.4 (Pharsight 
Corporation) assuming a non-compartmental model and 
linear trapezoidal interpolation.
Pharmacodynamics
The mice are injected with 30 mg/kg SAN9812 in a 0.9% 
NaCl solution subcutaneously. Before and after the injection 
blood was taken at different time points. The blood sam-
ples were incubated for 30 min at room temperature before 
being centrifuged at 2500g for 10 min. The supernatant as 
serum was used afterwards to determine the CN1 activity. 
Two groups of animals with three animals each were used, 
one with activity levels all below 45 µmol/(ml h) defined as 
the low-activity group and one with activity levels all above 
250 µmol/(ml h) defined as high-activity group. These two 
groups are depicted separately in the figures.
Pharmacodynamics upon subchronic administration
The mice were treated with 30 mg/kg SAN9812 in a 0.9% 
NaCl solution for 1 week by daily subcutaneous injection. 
Before and after the compound administration serum was 
taken and CN1 activity was measured. Animals were strati-
fied to high- and low-activity groups as described above and 
five mice per group were used.
Acute carnosine injection ± SAN9812 in mice
Carnosinase 1-overexpressing mice were supplemented with 
a bolus of 200 mg carnosine alone or in combination with 
30 mg/kg SAN9812 in a 0.9% NaCl solution by s.c. admin-
istration. hCN1-negative and hCN1-overexpressing mice 
served as controls (n = 5–8). Plasma samples were taken 
after 4 h and after 8 h. After 8 h, mice were sacrificed and 
kidneys were harvested.
Chemical analyses
A more extended description of chemical analyses can be 
found in the supplementary methods.
Sample preparation
Serum and EDTA plasma were taken according to standard 
protocols. For CN1, activity serum was taken, for carnosine 
measurement, EDTA plasma and tissue samples supple-
mented with 2 mmol EDTA were used.
CN1 activity
Carnosinase 1 activity was measured using a modified pro-
tocol based on the assay described by Teufel 2002. Details 
are in the supplementary methods.
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Carnosine concentration
Carnosine concentration was measured by high-perfor-
mance liquid chromatography as previously described 
(Schönherr 2002).
Figures and statistics
Figures were created using Microsoft Excel and GraphPad 
Prism 7.0. Error bars denote either standard deviation (SD) 
or standard error of the mean (SEM) as described in the 
individual figure legends. To compare different groups, 
ANOVA one-way with Holm-Sidak’s multiple comparison 
test were applied using GraphPad Prism 7.0.
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